When to stop propranolol for infantile hemangioma

Area of Science:

• Pediatric Dermatology
• Vascular Lesion Research
• Pharmacological Treatment

Background:

• Infantile hemangioma (IH) treatment requires careful consideration of propranolol discontinuation timing.
• Optimal timing for stopping propranolol therapy for IH remains unclear.
• Color Doppler ultrasound may aid in treatment management.

Purpose of the Study:

• To investigate factors influencing propranolol treatment outcomes in infantile hemangioma.
• To determine the optimal timing for propranolol discontinuation based on lesion regression.
• To assess the utility of ultrasound in guiding IH treatment cessation.

Main Methods:

• Retrospective analysis of 149 patients with infantile hemangioma treated with propranolol.
• Patients categorized into complete and partial lesion regression groups based on ultrasound findings.
• Comparison of treatment duration, discontinuation age, and recurrence rates between groups.

Main Results:

• Shorter propranolol treatment duration and younger discontinuation age were observed in the complete regression group.
• The complete regression group exhibited a lower recurrence rate.
• No significant differences in adverse event rates or follow-up duration were noted between groups.

Conclusions:

• Propranolol is effective for IH requiring intervention, but appropriate discontinuation timing is crucial.
• Lesion regression rate, assessed by ultrasound, is a key determinant for stopping propranolol.
• Earlier discontinuation, correlated with lesion regression, may lower IH recurrence rates.